{"success":true,"data":{"pressRelease":{"id":"132548","rtpr_id":"nBw1gVlX6a","ticker":"ENGN","exchange":"NASDAQ","all_tickers":["ENGN"],"title":"enGene to Participate in Upcoming Investor Conferences","author":"Business Wire","published_at":"2026-09-01T12:30:00.541Z","article_body":"enGene to Participate in Upcoming Investor Conferences\n\nenGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a\nclinical-stage, non-viral genetic medicines company today announced that\nmanagement will participate in the following investor conferences:\n\nWells Fargo 21(st) Annual Healthcare Conference\n\nDate: Tuesday, September 8, 2026\n\nTime: 10:15 a.m. ET\n\nFormat: Fireside Chat\n\nMorgan Stanley 24(th) Annual Global Healthcare Conference\n\nDate: Monday, September 14, 2026\n\nTime: 7:00 a.m. ET\n\nFormat: Fireside Chat\n\nH.C. Wainwright 28(th) Annual Global Investment Conference\n\nDate: Tuesday, September 15, 2026\n\nTime: 1:30 p.m. ET\n\nFormat: Corporate Presentation\n\nA live webcast of these events can be accessed on the “Events and\nPresentations” page under the “Investors” section of the enGene website\nat www.engene.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.engene.com&esheet=54597056&newsitemid=20260901720827&lan=en-US&anchor=www.engene.com&index=1&md5=4b02857e5b2a72687f0adfa9d05db856)\nand will be archived there for 90 days.\n\nAbout enGene\n\nenGene Therapeutics Inc. is a clinical-stage biotechnology company\nmainstreaming non-viral genetic medicine through the delivery of therapeutics\nto mucosal tissues and other organs, with the goal of creating new ways to\naddress diseases with high clinical needs. enGene’s lead program is\ndetalimogene voraplasmid (also known as detalimogene) for patients with\nnon-muscle invasive bladder cancer (NMIBC), a disease with a high clinical\nburden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND\nPhase 2 trial, which includes a pivotal cohort studying detalimogene in\nhigh-risk, Bacillus Calmette-Guérin (BCG)-unresponsive patients with\ncarcinoma in situ (CIS) with or without concomitant papillary disease.\n\nDetalimogene was developed using enGene’s proprietary Dually Derivatized\nOligochitosan (DDX) platform, which enables penetration of mucosal tissues and\ndelivery of a wide range of sizes and types of cargo, including DNA and\nvarious forms of RNA.\n\nTo learn more, please visit enGene.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2FenGene.com&esheet=54597056&newsitemid=20260901720827&lan=en-US&anchor=enGene.com&index=2&md5=1e69338ba11a7748dc955bd25168fc74)\nand follow us on LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fengene%2F&esheet=54597056&newsitemid=20260901720827&lan=en-US&anchor=LinkedIn&index=3&md5=b76623120485ef59ecf0273fe9a0eeb7)\n, X\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fx.com%2Fengene_inc&esheet=54597056&newsitemid=20260901720827&lan=en-US&anchor=X&index=4&md5=d6c70d9bbf73984d0187d3c16aa276f5)\nand BlueSky\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbsky.app%2Fprofile%2Fengeneinc.bsky.social&esheet=54597056&newsitemid=20260901720827&lan=en-US&anchor=BlueSky&index=5&md5=de47f9b2234f3f36be3e880ace474192)\n.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260901720827/en/\n(https://www.businesswire.com/news/home/20260901720827/en/)\n\nMedia and Investor Contact: \n\nLauren Hopfer\n\nLhopfer@engene.com (mailto:Lhopfer@engene.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw1gVlX6a","title":"enGene to Participate in Upcoming Investor Conferences","author":"Business Wire","ticker":"ENGN","created":"2026-09-01T12:30:00.541Z","tickers":["ENGN"],"exchange":"NASDAQ","article_body":"enGene to Participate in Upcoming Investor Conferences\n\nenGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a\nclinical-stage, non-viral genetic medicines company today announced that\nmanagement will participate in the following investor conferences:\n\nWells Fargo 21(st) Annual Healthcare Conference\n\nDate: Tuesday, September 8, 2026\n\nTime: 10:15 a.m. ET\n\nFormat: Fireside Chat\n\nMorgan Stanley 24(th) Annual Global Healthcare Conference\n\nDate: Monday, September 14, 2026\n\nTime: 7:00 a.m. ET\n\nFormat: Fireside Chat\n\nH.C. Wainwright 28(th) Annual Global Investment Conference\n\nDate: Tuesday, September 15, 2026\n\nTime: 1:30 p.m. ET\n\nFormat: Corporate Presentation\n\nA live webcast of these events can be accessed on the “Events and\nPresentations” page under the “Investors” section of the enGene website\nat www.engene.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.engene.com&esheet=54597056&newsitemid=20260901720827&lan=en-US&anchor=www.engene.com&index=1&md5=4b02857e5b2a72687f0adfa9d05db856)\nand will be archived there for 90 days.\n\nAbout enGene\n\nenGene Therapeutics Inc. is a clinical-stage biotechnology company\nmainstreaming non-viral genetic medicine through the delivery of therapeutics\nto mucosal tissues and other organs, with the goal of creating new ways to\naddress diseases with high clinical needs. enGene’s lead program is\ndetalimogene voraplasmid (also known as detalimogene) for patients with\nnon-muscle invasive bladder cancer (NMIBC), a disease with a high clinical\nburden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND\nPhase 2 trial, which includes a pivotal cohort studying detalimogene in\nhigh-risk, Bacillus Calmette-Guérin (BCG)-unresponsive patients with\ncarcinoma in situ (CIS) with or without concomitant papillary disease.\n\nDetalimogene was developed using enGene’s proprietary Dually Derivatized\nOligochitosan (DDX) platform, which enables penetration of mucosal tissues and\ndelivery of a wide range of sizes and types of cargo, including DNA and\nvarious forms of RNA.\n\nTo learn more, please visit enGene.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2FenGene.com&esheet=54597056&newsitemid=20260901720827&lan=en-US&anchor=enGene.com&index=2&md5=1e69338ba11a7748dc955bd25168fc74)\nand follow us on LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fengene%2F&esheet=54597056&newsitemid=20260901720827&lan=en-US&anchor=LinkedIn&index=3&md5=b76623120485ef59ecf0273fe9a0eeb7)\n, X\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fx.com%2Fengene_inc&esheet=54597056&newsitemid=20260901720827&lan=en-US&anchor=X&index=4&md5=d6c70d9bbf73984d0187d3c16aa276f5)\nand BlueSky\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbsky.app%2Fprofile%2Fengeneinc.bsky.social&esheet=54597056&newsitemid=20260901720827&lan=en-US&anchor=BlueSky&index=5&md5=de47f9b2234f3f36be3e880ace474192)\n.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260901720827/en/\n(https://www.businesswire.com/news/home/20260901720827/en/)\n\nMedia and Investor Contact: \n\nLauren Hopfer\n\nLhopfer@engene.com (mailto:Lhopfer@engene.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-09-01T12:30:00.587405178Z","server_sent_at_ms":1788265800587},"received_at":"2026-09-01T12:30:00.672Z","source_url":"https://www.businesswire.com/news/home/20260901720827/en/"},"analysis":{"id":"121450","press_release_id":"132548","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"enGene Therapeutics announced that management will participate in three investor conferences in September, including events hosted by Wells Fargo, Morgan Stanley, and H.C. Wainwright.\n\nThe presentations will be available via live webcast and archived on the company's website for 90 days.\n\nThe company is a clinical-stage biotechnology firm focused on non-viral genetic medicines, with its lead program detalimogene for non-muscle invasive bladder cancer currently in a Phase 2 trial.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine investor conference attendance."},"keyFigures":null,"quotedText":"","namedEntities":{"people":[{"name":"Lauren Hopfer","role":"Media and Investor Contact"}],"products":["detalimogene voraplasmid","detalimogene","Dually Derivatized Oligochitosan (DDX) platform"],"companies":[{"name":"enGene Therapeutics Inc.","ticker":"ENGN"},{"name":"Wells Fargo","relationship":"conference organizer"},{"name":"Morgan Stanley","relationship":"conference organizer"},{"name":"H.C. Wainwright","relationship":"conference organizer"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine administrative announcement regarding attendance at investor conferences. No material clinical, financial, or operational updates."},"tickerRelevance":{"others":[],"primary":"ENGN"},"globalImportance":5,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"conference-attendance"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"enGene Therapeutics announced that management will participate in three investor conferences in September, including events hosted by Wells Fargo, Morgan Stanley, and H.C. Wainwright.\n\nThe presentations will be available via live webcast and archived on the company's website for 90 days.\n\nThe company is a clinical-stage biotechnology firm focused on non-viral genetic medicines, with its lead program detalimogene for non-muscle invasive bladder cancer currently in a Phase 2 trial.","key_figures":null,"named_entities":{"people":[{"name":"Lauren Hopfer","role":"Media and Investor Contact"}],"products":["detalimogene voraplasmid","detalimogene","Dually Derivatized Oligochitosan (DDX) platform"],"companies":[{"name":"enGene Therapeutics Inc.","ticker":"ENGN"},{"name":"Wells Fargo","relationship":"conference organizer"},{"name":"Morgan Stanley","relationship":"conference organizer"},{"name":"H.C. Wainwright","relationship":"conference organizer"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-01T14:14:14.936Z","global_importance":5,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"conference-attendance"}},"durationMs":160012,"modelName":"glm-4.7"}}